274 related articles for article (PubMed ID: 35694260)
1. Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis.
Xiang Z; Li J; Zhang Z; Cen C; Chen W; Jiang B; Meng Y; Wang Y; Berglund B; Zhai G; Wu J
Front Pharmacol; 2022; 13():883655. PubMed ID: 35694260
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
[TBL] [Abstract][Full Text] [Related]
4. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA; Caridà G; Ciliberto D; d'Apolito M; Pelaia C; Caracciolo D; Riillo C; Correale P; Galvano A; Russo A; Barbieri V; Tassone P; Tagliaferri P
ESMO Open; 2022 Jun; 7(3):100465. PubMed ID: 35427835
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
9. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.
Mei T; Wang T; Deng Q; Gong Y
Front Immunol; 2023; 14():1062679. PubMed ID: 36825025
[TBL] [Abstract][Full Text] [Related]
10. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016
[TBL] [Abstract][Full Text] [Related]
11. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis.
Huang Q; Zheng Y; Gao Z; Yuan L; Sun Y; Chen H
J Cancer; 2021; 12(4):1133-1143. PubMed ID: 33442411
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
[TBL] [Abstract][Full Text] [Related]
14. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
15. Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies.
Jiang M; Liu C; Ding D; Tian H; Yu C
Front Oncol; 2022; 12():827050. PubMed ID: 35619899
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials.
Jin C; Qi J; Wang Q; Pu C; Tan M
Front Oncol; 2023; 13():1158690. PubMed ID: 37124488
[TBL] [Abstract][Full Text] [Related]
18. A Network Meta-Analysis of Cancer Immunotherapies
Herbst R; Jassem J; Abogunrin S; James D; McCool R; Belleli R; Giaccone G; De Marinis F
Front Oncol; 2021; 11():676732. PubMed ID: 34307144
[TBL] [Abstract][Full Text] [Related]
19. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers.
Al-Showbaki L; Nadler MB; Desnoyers A; Almugbel FA; Cescon DW; Amir E
J Cancer; 2021; 12(14):4372-4378. PubMed ID: 34093837
[No Abstract] [Full Text] [Related]
20. Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma.
Chen HL; Tu YK; Chang HM; Lee TH; Wu KL; Tsai YC; Lee MH; Yang CJ; Hung JY; Chong IW
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
